A decrease in the level of RXRβ has already been correlated with schizophrenia, and RXR agonist—bexarotene—is currently in the third clinical trial phase for the reduction of positive symptoms of schizophrenia [22, 43–45]. This evidence concerns the gene RXRB and schizophrenia.